Effect of coexistent adverse cytogenetics on the PFS and OS of patients with hyperdiploidy when subdivided by pathway and chemotherapy
| . | Survival, median mo (95% CI) . | Log-rank test (P) . | |
|---|---|---|---|
| HRD, no adverse lesion . | HRD + any adverse lesion . | ||
| PFS | |||
| Intensive pathway (CVAD/CTD) | 34.1 (27.5, 40.7) | 20.1 (17.5, 22.6) | <.001 |
| Nonintensive pathway (MP/CTDa) | 14.5 (12.1, 16.9) | 13.1 (12.4, 14.6) | <.001 |
| Thalidomide chemotherapy (CTD/CTDa) | 25.4 (17.4, 33.4) | 17.5 (13.7, 21.3) | .002 |
| Traditional chemotherapy (CVAD/MP) | 21.6 (15.8, 27.4) | 13.9 (14.7, 19.1) | <.001 |
| OS | |||
| Intensive pathway (CVAD/CTD) | 97.0 (74, —) | 43.5 (32.0, 55.0) | <.001 |
| Nonintensive pathway (MP/CTDa) | 38.5 (31.8, 45.2) | 28.9 (22.8, 35.0) | .047 |
| Thalidomide chemotherapy (CTD/CTDa) | 73.3 (52.4, 94.2) | 44.1 (32.3, 55.9) | .014 |
| Traditional chemotherapy (CVAD/MP) | 57.6 (49.1, 66.1) | 29.9 (24.9, 34.9) | <.001 |
| . | Survival, median mo (95% CI) . | Log-rank test (P) . | |
|---|---|---|---|
| HRD, no adverse lesion . | HRD + any adverse lesion . | ||
| PFS | |||
| Intensive pathway (CVAD/CTD) | 34.1 (27.5, 40.7) | 20.1 (17.5, 22.6) | <.001 |
| Nonintensive pathway (MP/CTDa) | 14.5 (12.1, 16.9) | 13.1 (12.4, 14.6) | <.001 |
| Thalidomide chemotherapy (CTD/CTDa) | 25.4 (17.4, 33.4) | 17.5 (13.7, 21.3) | .002 |
| Traditional chemotherapy (CVAD/MP) | 21.6 (15.8, 27.4) | 13.9 (14.7, 19.1) | <.001 |
| OS | |||
| Intensive pathway (CVAD/CTD) | 97.0 (74, —) | 43.5 (32.0, 55.0) | <.001 |
| Nonintensive pathway (MP/CTDa) | 38.5 (31.8, 45.2) | 28.9 (22.8, 35.0) | .047 |
| Thalidomide chemotherapy (CTD/CTDa) | 73.3 (52.4, 94.2) | 44.1 (32.3, 55.9) | .014 |
| Traditional chemotherapy (CVAD/MP) | 57.6 (49.1, 66.1) | 29.9 (24.9, 34.9) | <.001 |
CI, confidence interval; CTD, cyclophosphamide, thalidomide, and dexamethasone; CTDa, as CTD with attenuated dosing; CVAD, cyclophosphamide, vincristine, doxorubicin, and dexamethasone; MP, melphalan and prednisolone.